British pharmaceutical company GSK said on Wednesday that it has agreed to pay $2.3 billion to put an end to lawsuits in ... to pay $70 million to settle a separate Zantac case with US laboratory ...

GSK, Sanofi and Boehringer Ingelheim. Last month, Sanofi reached an agreement in principle to settle 4,000 lawsuits linking ...

GSK has opted to settle a key lawsuit ... will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer.

The three-day hearing comes a few months after GSK decided to settle a complaint brought ... The common claim in the lawsuits is that a contaminant in Zantac (ranitidine) called N ...

A trial ended with a hung jury on Thursday in a California man's lawsuit alleging Boehringer Ingelheim's discontinued ...

A recent ruling has determined a $2.2 billion payout to settle 93% of cases ... Thousands of lawsuits have been filed against GSK, claiming their antacid Zantac caused a greater risk of cancer ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

The lawsuits arose after recipients of GSK’s heartburn drug Zantac claimed it caused cancer. Chief executive Emma Walmsey said the move to settle around 80,000 lawsuits across the US – covering about ...

GSK plc (NYSE:GSK) – GSK agreed to pay up to $2.2 billion to settle 93% of U.S. lawsuits related to Zantac, alleging the drug caused cancer. The settlement, announced Wednesday, was lower than ...

Thousands of lawsuits have been filed against GSK, claiming their antacid Zantac caused a greater risk ... was in the company's fiscal interest to settle the lawsuits in order to appease ...